Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms EXCEL
- Sponsors Abbott Laboratories
- 31 Oct 2016 Primary endpoint has been met. (Composite measure of all-cause mortality, myocardial infarction (MI) or stroke)
- 31 Oct 2016 Results published in the New England Journal of Medicine
- 23 Oct 2014 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2016 as reported by ClinicalTrials.gov record.